Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 43 - Drugs for specific purposes, not provided for in groups
Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317)
12/2002
12/12/2002WO2002098462A1 Remedies containing aldose reductase inhibitor as the active ingredient for demyelinating diseases or diseases associated with demyelination
12/12/2002WO2002098459A2 USE OF IgM ANTIBODIES AGAINST dsDNA IN SYSTEMIC LUPUS ERYTHEMATOSUS WITH NEPHRITIS
12/12/2002WO2002098458A1 Sphingosine kinase interacts with traf2 and modulates tumor necrosis factor-induced cellular activity
12/12/2002WO2002098453A2 Orally administering parathyroid hormone and calcitonin
12/12/2002WO2002098446A1 Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
12/12/2002WO2002098444A2 Use of hepcidin for preparing a medicament for treating disorders of iron homeostasis
12/12/2002WO2002098438A1 Compositions containing an active fraction isolated from scutellariae barbatae and methods of use
12/12/2002WO2002098428A1 Tetracyclic compounds as pde5-inhibitors
12/12/2002WO2002098427A2 Sustained-release analgesic compounds
12/12/2002WO2002098426A1 Substituted tetrahydroisoquinolines for use in the treatment of inflammatory diseases
12/12/2002WO2002098422A1 Use of methylnaltrexone to treat immune suppression
12/12/2002WO2002098418A1 Combination comprising a p-gp inhibitor and an anti-epileptic drug
12/12/2002WO2002098416A2 Antineoplastic combinations
12/12/2002WO2002098413A2 Pharmaceutical compositions comprising orlistat and fatty acids and/or salts thereof
12/12/2002WO2002098406A1 Novel compounds and compositions as cathepsin inhibitors
12/12/2002WO2002098405A1 Liver fibrosis inhibitors
12/12/2002WO2002098400A1 Novel arylaminopropane analogues and their use for the treatment of glaucoma
12/12/2002WO2002098363A2 NON-PEPTIDE GnRH AGENTS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THEIR USES, AND PROCESSES FOR PREPARING THEM
12/12/2002WO2002098362A2 Use of rank antagonists to treat cancer
12/12/2002WO2002098356A2 Ppp2cs as modifiers of the p53 pathway and methods of use
12/12/2002WO2002098352A2 PHARMACEUTICAL COMPOSITIONS FOR THE COORDINATED DELIVERY OF NSAIDs
12/12/2002WO2002098350A2 Pyranoindazoles and their use for the treatment of glaucoma
12/12/2002WO2002098347A2 Methods and compositions that affect melanogenesis (pfi-016cip/pct)
12/12/2002WO2002098278A2 Peripheral blood fibrocytes differentiation pathway and migration to wound sites
12/12/2002WO2002087600A8 Use of phyllanthus constituents for treating or preventing infections caused by hepatit
12/12/2002WO2002076982A3 Non-nucleoside reverse transcriptase inhibitors
12/12/2002WO2002076977A3 Rho-kinase inhibitors
12/12/2002WO2002076976A3 Rho-kinase inhibitors
12/12/2002WO2002074798A3 The genome of a bifidobacterium
12/12/2002WO2002074756A3 Urokinase inhibitors
12/12/2002WO2002074327A3 Compositions and methods for treating gonadotrophin related illnesses
12/12/2002WO2002072548A3 Heterocyclic compounds and their use as histamine h4 ligands.
12/12/2002WO2002067954A3 Use of particulate biocomplex bk-riv for producing a medicament for protecting and reconstructing the hepatic parenchyma
12/12/2002WO2002067848A3 PEPTIDES FROM THE 16/6id ANTIBODY FOR TREATING SLE
12/12/2002WO2002066458A3 2-thio-substituted imidazole derivatives and the use thereof in the pharmaceutical industry
12/12/2002WO2002065989A3 Aminoglycoside treatment for lysosomal storage diseases
12/12/2002WO2002064552A8 1g(a)-AMINO-N-HYDROXY-ACETAMIDE DERIVATIVES
12/12/2002WO2002064543A3 Novel succinate salt of o-desmethyl-venlafaxine
12/12/2002WO2002064080A3 Matrix metalloproteinase inhibitors
12/12/2002WO2002062792A9 Jnk inhibitor
12/12/2002WO2002059612A3 Animal model and cell-line expressing modified chlorine channel
12/12/2002WO2002057252A3 Heterocyclic sulfonamide inhibitors of beta amyloid production
12/12/2002WO2002045686A3 Pharmaceutical paste comprising an acid-labile active ingredient
12/12/2002WO2002030983A3 Plasma fraction containing bikunin, method for the production thereof and use of the same
12/12/2002WO2002024749A3 Isolated human transporter proteins, nucleic acid molecules encoding them, and uses thereof
12/12/2002WO2002018593A3 Modulation of fas and fasl expression
12/12/2002WO2002008292A3 Human monoclonal antibody against hepatitis c virus e2 glycoprotein
12/12/2002WO2002004424A9 Pyrazole derivatives
12/12/2002WO2002002775A3 Calpain protease 12
12/12/2002WO2001097850A3 Combinations and compositions which interfere with vegf/vegf and angiopoietin/tie receptor function and their use (ii)
12/12/2002WO2001093983A9 Secreted and transmembrane polypeptides and nucleic acids encoding the same
12/12/2002WO2001089568A9 Nrg-2 nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods
12/12/2002WO2001078720A8 Decreasing the intracellular level of beta-catenin by administering hydroxymatairesinol
12/12/2002WO2001054731A3 Ligand conjugates and methods for preparing same
12/12/2002WO2001042272A9 Eplerenone crystalline form exhibiting enhanced dissolution rate
12/12/2002WO2000032152A3 Compositions and methods for regulating bacterial pathogenesis
12/12/2002US20020188240 Process and apparatus for utilization of in vivo extracted plasma with tissue engineering devices, bioreactors, artificial organs, and cell therapy applications
12/12/2002US20020188143 Steroid compounds, use of these compounds for the preparation of meiosis-regulating medicaments and method for the preparation of these compounds
12/12/2002US20020188139 P-thienylbenzylamides as agonists of angiotensin-(1-7) receptors, and methods of their preparartion and use
12/12/2002US20020188134 Pharmaceutical compositions
12/12/2002US20020188128 Substituted imidazo[1,2-A] pyridine derivatives
12/12/2002US20020188124 Novel spiro compounds
12/12/2002US20020188122 Such as pyridine-4-carboxaldehyde-(4-Morpholinylprop-3-yl) imine for use in therapy as cytokine inhibitors
12/12/2002US20020188118 Compounds and methods for the inhibition of the expression of VCAM-1
12/12/2002US20020188107 Plant protein for use in the treatment of cancer
12/12/2002US20020188100 Boron compound for use in the treatment of stroke, heart defects, inflammation, autoimmune and cancer disease
12/12/2002US20020188029 Methods of treating or preventing weight gain, obesity, and related disorders
12/12/2002US20020188018 3-indolyl-4-phenyl-1H-pyrrole-2,5-dione derivatives as inhibitors of glycogen synthase kinase-3beta
12/12/2002US20020188017 Thienylazolylalkoxyethanamines, their preparation and their application as medicaments
12/12/2002US20020188015 Method and composition for rejuvinating cells, tissues organs, hair and nails
12/12/2002US20020188007 Pyrazolecarboxylic acid derivatives, their preparation and pharmaceutical compositions containing them
12/12/2002US20020188004 Heterocycle carboxamides as antiviral agents
12/12/2002US20020188000 Imidazo-pyridine derivatives as ligands for gaba receptors
12/12/2002US20020187996 Prevention of addiction in pain management
12/12/2002US20020187994 New compounds
12/12/2002US20020187992 Prodrugs via acylation with cinnamate
12/12/2002US20020187991 Barbituric acid derivatives
12/12/2002US20020187989 Preventive or therapeutic drugs for various eosinophilia-related diseases containg chymase inhibitors as the active ingredient
12/12/2002US20020187982 Glucagon antagonists/inverse agonists
12/12/2002US20020187978 4-Heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors
12/12/2002US20020187976 New benzofurane derivatives, their preparation process, their use as medicaments and the pharmaceutical compositions containing them
12/12/2002US20020187973 Pharmaceutical compositions and uses for androst-5-ene-3beta, 17beta-diol
12/12/2002US20020187972 Methods for modulating expression of exogenous genes in mammalian systems
12/12/2002US20020187970 Pharmaceutical compositions and uses for androst-5-ene-3beta, 17beta-DIOL
12/12/2002US20020187969 Pharmaceutical compositions and uses for androst-5-ene-3beta, 17beta-diol
12/12/2002US20020187968 Pharmaceutical compositions and uses for androst-5-ene-3beta, 17beta-DIOL
12/12/2002US20020187967 Pharmaceutical compositions and uses for androst-5-ene-3beta, 17beta-diol
12/12/2002US20020187966 Pharmaceutical compositions and uses for androst-5-ene-3beta, 17beta-diol
12/12/2002US20020187965 Pharmaceutical compositions and uses for androst-5-ene-3beta, 17beta-diol
12/12/2002US20020187964 Pharmaceutical compositions and uses for androst-5-ene-3beta, 17beta-diol
12/12/2002US20020187963 Pharmaceutical compositions and uses for androst-5-ene-3beta, 17beta-diol
12/12/2002US20020187962 Pharmaceutical compositions and uses for androst-5-ene-3beta, 17beta-diol
12/12/2002US20020187956 Method for treating tumors by the administration of tegafur, uracil, folinic acid, and cyclophosphamide
12/12/2002US20020187946 Mammalian iap gene family, primers, probes and detection methods
12/12/2002US20020187943 Bioavailable composition of natural and synthetic hca
12/12/2002US20020187941 Pregabalin lactose conjugates
12/12/2002US20020187939 Use of inhibitors of the renin-angiotensin system
12/12/2002US20020187938 Ghrelin antagonists
12/12/2002US20020187936 Methods of treating liver disease and liver damage with growth hormone and foxM1B
12/12/2002US20020187933 Cardiovascular disorders; regeneration of heart tissue
1 ... 849 850 851 852 853 854 855 856 857 858 859 860 861 862 863 864 865 866 867 868 869 ... 1564